Auriga Upgrades Myriad Genetics (MYGN) from Sell to Buy; The Bar Has Been Reset
Tweet Send to a Friend
Auriga upgrades Myriad Genetics (Nasdaq: MYGN) from Sell to Buy. PT increased from $19 to $23.
Auriga analyst says, "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Auriga analyst says, "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
